OBJECTIVE Several studies have been published in 2009 suggesting a possible association between insulin glargine and increased risk of malignancies, including breast cancer. The objective of this study was to assess the relation between the individual insulins (glargine, aspart, lispro and human insulin) and development of breast cancer.
Several studies have suggested an association between the risk of malignancies and the therapeutic use of insulin (1, 2) . Insulin therapies include human insulin, analogs of human insulin, and animal insulin. Following the simultaneous publication of three studies comparing different insulin preparations for associated cancer risk, it was suggested that users of glargine, a long-acting insulin analogue, had an increased risk of cancer and particularly of breast cancer (3) (4) (5) . As a result, the European Medicines Agency (EMA) and the UnitedStates Food and Drug Administration (FDA) issued an alert in July 2009 informing healthcare professionals and patients about a possible increase of cancer incidence in glargine users (6, 7) . These studies had important methodological limitations, including lack of proper control for breast cancer risk factors, (8, 9) and their results were not subsequently confirmed (10) .
The objective of this international case-control study was to assess the relation between use of individual types of insulin (glargine, aspart, lispro and human insulin) and development of breast cancer, controlling for breast cancer risk factors, type, severity and history of diabetes, and comorbidities (11) .
RESEARCH DESIGN AND METHODS

Study population
In this case-control study, breast cancer cases and community controls were women aged 18 years and over, who had been treated for type 1 or type 2 diabetes with any type of antidiabetic drugs (oral and insulin) for at least three months, were alive and able to answer a telephone interview and living in the United Kingdom (England and Scotland), Canada (Quebec, Ontario and New-Brunswick) or France (nationwide). Women previously treated for gestational diabetes for less than 3 months or suffering from psychiatric or other medical conditions preventing participation were excluded. Recruitment took place between January 2010 and June 2012.
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Cases
Cases of breast cancer were identified in oncology clinics that treated more than 100 breast cancer patients annually in each participating country/region. Pathology records were searched to identify women meeting the aforementioned inclusion and exclusion criteria and who had a first lifetime pathologically-confirmed diagnosis of breast cancer between January 1, 2008 and June 30, 2009 , which corresponds to the eighteen-month period prior to the international alert issued on glargine. All hospital charts were reviewed, and patients whose records suggested a history of diabetes (type 1 or type 2) were invited to participate in the study. Information was collected from computerized oncology records on the type of breast cancer (in situ, ductal or lobular, primary invasive), TNM classification, examinations and treatments. Based on TNM, cancer was secondarily staged from 0 to 4 according to the American Joint Committee on Cancer (AJCC version 7) classification. Types of breast cancer tumors were also classified as HER2 positive, luminal or triple negative.
Controls
Controls were identified through a pool of referents recruited by networks of GPs participating in the Pharmacoepidemiologic General Research eXtension (PGRx) program.
This research network systematically recruits representative patients from general practice using a methodology that has been previously validated in risk-assessment studies (12) . In this particular instance the PGRx recruitment system consisted, in each participating country and region, of a random sample of participating GPs instructed to identify and invite all their patients diagnosed with diabetes before June 30, 2009 (and meeting all of the inclusion and exclusion criteria mentioned above) to participate in the study.
Data collection
History of diabetes, risk factors and prescriptions were obtained from each participant's own diabetologist and/or GP involved in the treatment of their diabetes (cases and controls). 
Exposure to insulin
Objective prescribing information on insulin from physicians and/or pharmacists was obtained in 84.4% of patients (i.e., information provided by physicians and/or pharmacists).
In the remaining patients, data on insulin exposure was obtained from the patient interview only (see below). Agreement between patient interviews and physicians' records for insulin use was 97% (kappa > 0.89) in patients where information from both sources was available.
Given that all patients underwent an interview, the primary analysis used the data collected during the interview while objective data from prescriptions was used in sensitivity analyses.
The time-window retained a priori for the primary analysis was insulin use in the 8-year period preceding the index date defined as the date of first diagnostic biopsy confirming breast cancer for the case. An identical time window was used for the controls so as to match Detailed history for each category of treatment before the index date was collected: start/stop dates, doses, and switching. The total duration of each insulin use period was computed.
Patients who reported to have used insulin for less than 3 months (total treatment duration)
were classified as non-exposed to insulin. Doses were classified as either lower or higher than the median value for each individual insulin use in controls. Use of any insulin prior to the 8-year time window of interest was defined as "past-insulin use" without distinction between individual types of insulin.
Statistical analysis
The statistical analysis plan was finalized before the start of data collection.
Participants were compared to non-participants for age, cancer stage (for cases), and antidiabetic treatments (oral therapy and insulin use). Given that some patients were dead by the time the study began, death rates according to the type of anti-diabetic treatment (oral, glargine and other individual insulins) reported in the records were computed in order to detect a potential survival bias.
Matching
Once all cases and potential controls were interviewed, controls were randomly matched to cases on five criteria: type of diabetes (type 1 or 2), country region or province, age at recruitment (± 1 year if possible, otherwise ± 2, 3, 4 or 5 years), date of recruitment (± 6 months) and referral to an endocrinologist (diabetologist) for diabetes (Yes/No). The objective was to obtain on average four matched controls per breast cancer case.
Modeling diabetes risk factors and insulin exposure
A multivariate confounding breast cancer risk score was computed to be used as adjustment categories containing users and non-users of other insulins. These ORs were mutually adjusted and reflect the association of breast cancer with the insulin product considered adjusted for the use of other insulins. Sensitivity analyses were performed in users of at least one insulin treatment in the past and in users of at least one insulin treatment in the 8-year time window. Looking specifically at glargine, a stratified analysis by duration of glargine use (<4 years and ≥4 years) and by maximum dose used (below or above median dose in the study population, i.e. 27 UI) was performed. Additionally, breast cancer risk estimates associated with glargine were compared to every other insulin by computing all ratios using the variance-covariance matrix of logistic model parameters.
No variable used in the analyses had more than 5% of missing values. In all multivariate models, missing values were imputed by median (if continuous) or mode (if categorical). The study was powered to detect an odds ratio as small as 1.4 for glargine use and breast cancer.
Recruitment was stratified by country (U.K., France and Canada) to account for variations in glargine use and ensure sufficient exposure. Analyses were performed using the SAS® software (version 9.1.3; SAS Institute Inc., Cary, North Carolina, USA).
Ethics
The study protocol, consent forms and methods for protecting the confidentiality of patients were approved by institutional review boards across the three participating countries.
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Research ethics committees' approval was obtained for each participating institution and for recruitment by GPs in the U.K. and Canada. In France, ethics approval was obtained from the
Commission nationale de l'informatique et des libertés (CNIL) and from the Conseil national
de l'ordre des médecins (CNOM). Written informed consent was obtained from each participating patient. Physicians received fixed fees for their participation but not patients.
RESULTS
Description of cases and controls
Overall, 92 participating oncology centers (39 in the U.K., 38 in France, and 15 in Canada) reviewed a total of 39 558 medical records of women with a pathologically confirmed first lifetime diagnosis of breast cancer made between January 1, 2008 and June 30, 2009 ( Figure   1 ). Among them, 3 131 (7.9%) breast cancer patients were found to have a record of diabetes in the chart, of which 396 (12.6%) were dead at the time of study. Death rates were higher in insulin users than in non-users, but were comparable between users of any insulin (18%) and users of glargine (17% For controls, 580 GPs across the three countries recruited 5329 patients with diabetes agreeing to participate in the study (Figure 2 ) which was estimated (using respective national statistics) to represent between 44% and 52% of the expected clientele with diabetes seen in general practices, a participation rate similar to that of cases. Subsequently, 769 patients (14.4%) were identified as not meeting the inclusion and exclusion criteria and further 890 (16.7%) could not be reached for the interview, leaving 3670 control patients available for matching to each case.
After the matching procedure, 22 cases and 620 controls could not be matched leaving a final study population of 775 breast cancer cases (21% from the U.K., 15.5% from Canada, and 63.5% from France) and 3050 controls for a mean of 3.9 controls per case (range: 1-10).
Cases and controls did not show major differences for variables concerning lifestyle, medications use and utilization of healthcare services ( The probability of a case to fall within the fourth quartile of the computed breast cancer risk score was much higher than controls (2.74 [2.05-3.68]). Table 2 presents the main features of diabetes history and management which were very similar between cases and controls for all the variables studied. The distribution of the two types of diabetes by matching was identical in cases and controls with 6.2% for type 1 diabetes. Use of any insulin (cases and controls combined) was independently and significantly associated with longer duration of diabetes, HbA1c >8% (>64 mmol/mol), cardiovascular comorbidities as well as recent hospitalization (≤1 year) (data not shown). No significant association with insulin use was found for current (Table 3) .
CONCLUSIONS
This international case-control study was specifically designed to address the question of breast cancer risk among patients with diabetes using different insulin regimens and was carefully designed to minimize the risk of biases common to this type of studies. The nodifference findings in breast cancer risk in users of any of the individually studied insulin A common issue inherent to studies conducted by record linkage of healthcare databases is that it usually allows access to a limited number of risk factors for the control of confounding.
In our study, however, a large number of risk factors were considered and carefully evaluated.
Unexpectedly, the analysis showed no impact from the inclusion of these factors into risk models on odds ratio estimates: crude and adjusted odds ratios were similar.
Interpretation
Exposure to insulin was thoroughly documented within the eight-year time window (2001 to 2009), therefore spanning all potential exposures to glargine and other insulin analogs before the alert on insulin glargine and breast cancer was issued. Documenting past insulin use before that time window (obtained through patient interviews) allowed controlling for potential cumulative insulin effects. Still, the eight-year time window remains a relatively short period for cancer latency, but it might be sufficient to cover any potential effect on tumor growth. Moreover, very few patients had been continuously exposed to one specific type of insulin during the whole eight-year period. Among glargine users, only one-third had been exposed to that insulin during four years or more. For other insulins, exposure durations lasted for less than four years in the majority of users. Human insulin is a growth factor for different tumors in vitro and elevated levels of circulating endogenous insulin produce a secondary increase of insulin growth factor-1 (IGF-1) in vivo. This has been shown to Page 14 of 34 Diabetes Care accelerate the progression of cancer foci (19) (20) (21) (22) ). Glargine's affinity for the IGF-1 receptor is very high, which justifies concerns about its potential ability to promote cancer growth.
However, it was shown recently that glargine itself is rapidly metabolized and that its metabolites have lower affinity for IGF-1 than endogenous insulin (23) . In our study, the prevalence of glargine use was similar for all tumor stages (0 to 4) and types (luminal, HER2 positive or triple negative) studied, which was reassuring in this respect.
Strengths and limitations
The main strength of this study was the comprehensive procedure by which drug exposure and information on individual risk factors (24) were collected, using a methodology that has been previously used and validated (12, 13) . Data was collected from clinical practice, which allowed thorough documentation of patients' history of diabetes, including severity, comorbidities and management by either diabetologists or general practitioners. It accurately documented the prevalence of known risk factors for breast cancer allowing their adjustment in the analyses. Crossing data from physicians' records and standardized patient interviews allowed to establish the lifetime history of insulin treatment, documenting the time between first diagnosis of diabetes and first insulin therapy, as well as different individual insulin regimens used during and prior to the time window of interest for this study.
The case-control design of this study is the best suited to test hypotheses on risk of relatively rare events but has several limitations. First, selection bias can occur when identification of cases is associated with exposure status. The large number of breast cancers screened (39 558) to identify patients exposed to anti-diabetic drugs, by trained research assistants independently from the investigators, reduced this possibility. Nevertheless, based on data from oncology records, the participation of patients was not independent of exposure. Overall, 51% of patients declaring themselves as glargine users agreed to participate in the study compared to 41% for users of any other type of insulin. This difference was due to cases from Case-control studies are mostly at risk of recall bias where the exposure of interest is more likely to be reported by patients experiencing the condition of interest (i.e., cancer).
Precautions to prevent this bias included collecting medical prescriptions and records from health professionals and crossing the latter information with interviews, which gave excellent agreement for insulin use (97%). Sensitivity analyses using one or the other source of information did not change the results. Also, a potential recall bias would work in favor of an association between glargine and breast cancer. Another bias could arise from a diagnosis (of cancer) that is not blinded to exposure status. This is why this study was conducted only in cases diagnosed before the issued alert. The fact that the prevalence of glargine use was similar across the different stages of cancer is also reassuring in this respect as "lead-time bias" (when early diagnosis falsely appears to prolong survival) is thus less likely.
A disadvantage of the case-control approach is that only patients alive at the time of the interview could be included. A survival effect was unlikely to bias the comparison between different types of insulin because the death rate in cancer cases at the time of recruitment in the study was the same in glargine users (17%) as opposed to other insulin users (18%).
Another important potential limitation may be attributed to the relatively low participation rate. Our study was powered a priori to detect an odds ratio of at least 1.4 for glargine use relative to non-use of insulin based on the recruitment of 750 cases and 3000 controls. This required screening nearly 40 000 incident breast cancers, which is equivalent to the number of were also representative of patients with this disease in current practice, providing reasonable evidence of representativeness of the study population. Computation of breast cancer risk for factors such as reproductive history, HRT and oral contraceptives, was consistent with previously reported data. We did not observe, however, a risk with obesity, which has been frequently associated with a higher risk of breast cancer (29) . This may be explained by the fact that the majority of our patients (cases and controls) were overweight or obese.
Finally, this case-control study assessed only one cancer site (breast cancer). Recent studies on individual insulin use and cancer have provided additional information on other cancers.
The continuation of the ORIGIN trial over 6 years found no evidence of increased risk for any type of cancer (30) . The same was true for a number of recent healthcare database studies (31, 32) .
In conclusion, this international case-control study specifically conducted to address the risk of individual insulin use and incident breast cancer after a mean exposure of 3.2 years, found no increased risk with none of the individual insulin studied (glargine, lispro, aspart and human insulin). Longer-term studies are needed to further explore this issue.
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